TREATMENT PATTERNS OF ADVANCED EGFR-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) IN LATIN AMERICA

被引：0
|
作者：
Alves, J. S. [1 ]
Watanabe de Oliveira, R. [1 ]
Oliveira, D. [2 ]
Medina, Y. [3 ]
Osorio, M. [4 ]
Tabares, M. [5 ]
Tamayo, C. [6 ]
Kano, B. [7 ]
Muller Bernz, I [7 ]
机构：
[1] Janssen Cilag Farmaceut Ltda, Sao Paulo, Brazil
[2] Johnson & Johnson Med Brazil, Sao Paulo, Brazil
[3] Johnson & Johnson, Janssen Pharmaceut Co, Bogota, Cun, Colombia
[4] IQVIA, Mexico City, DF, Mexico
[5] IQVIA, Buenos Aires, DF, Argentina
[6] IQVIA, Bogota, Cun, Colombia
[7] IQVIA, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
SA56
引用
收藏
页码：S552 / S552
页数：1
相关论文
共 50 条
  • [1] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [2] Indirect treatment comparisons of relative efficacy for aumolertinib vs osimertinib in EGFR-positive non-small cell lung cancer (NSCLC)
    Popat, S.
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ali, S.
    Miller, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1012 - S1013
  • [3] Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer
    Ezeife, D.
    Kirk, V.
    Coyte, P.
    Nixon, N.
    Hancock-Howard, R.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S675 - S675
  • [4] Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America
    Arrieta, Oscar
    Felipe Cardona, Andres
    Federico Bramuglia, Guillermo
    Gallo, Aly
    Campos-Parra, Alma D.
    Serrano, Silvia
    Castro, Marcelo
    Aviles, Alejandro
    Amorin, Edgar
    Kirchuk, Ricardo
    Cuello, Mauricio
    Borbolla, Jose
    Riemersma, Omar
    Becerra, Henry
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : 1955 - 1959
  • [5] Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option
    Passaro, Antonio
    de Marinis, Filippo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S100 - S102
  • [6] Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients
    Tan, Xueyun
    Wang, Sufei
    Xia, Hui
    Chen, Hebing
    Xu, Juanjuan
    Meng, Daquan
    Wang, Zhihui
    Li, Yan
    Yang, Lian
    Jin, Yang
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 463 - 472
  • [7] A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
    Cortellini, Alessio
    Ficorella, Corrado
    Crisci, Roberto
    Divisi, Duilio
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6107 - 6111
  • [8] Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting
    Boyne, D. J.
    Jarada, T.
    Yusuf, A.
    O'Sullivan, D. E.
    Hu, L. X. Y.
    Brenner, D. R.
    Abbie, E.
    Rose, J. B.
    Eaton, K.
    Ewara, E. M.
    Cheung, W. Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S56 - S56
  • [9] Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study
    Maezawa, Yosuke
    Taguchi, Manato
    Kawakami, Takeshi
    Inui, Toshihide
    Okauchi, Shinichiro
    Numata, Takeshi
    Shiozawa, Toshihiro
    Miyazaki, Kunihiko
    Nakamura, Ryota
    Iguchi, Kesato
    Endo, Takeo
    Sakamoto, Tohru
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2024, 44 (04) : 1751 - 1757
  • [10] IMPROVING TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4038 - 4038
12345